Blog
RSS FeedPosted by Michael Wonder on 07 Apr 2020
Mallinckrodt initiates rolling submission of biologics license application for StrataGraft regenerative skin tissue to U.S. FDA
6 April 2020 - Application is supported by data from pivotal phase 3 study for the treatment of deep partial-thickness thermal ...
Posted by Michael Wonder on 07 Apr 2020
Bristol Myers Squibb expands patient support programs to help newly uninsured patients in the U.S.
7 April 2020 - Bristol Myers Squibb today announced an expansion of its existing patient support programs to help eligible ...
Posted by Michael Wonder on 07 Apr 2020
Novartis announces first European donation of hydroxychloroquine to Switzerland
3 April 2020 - Novartis has committed to making a global donation of up to 130 million doses of the anti-malarial ...
Posted by Michael Wonder on 07 Apr 2020
Essential work to combat the COVID-19 pandemic to continue during EMA's Easter break from 9 to 13 April 2020
7 April 2020 - It is EMA's top priority to help save lives during the pandemic by expediting the development ...
Posted by Michael Wonder on 07 Apr 2020
New $35 co-pay now available through Lilly insulin value program in response to COVID-19 crisis in U.S.
7 April 2020 - Insulin savings available for people with commercial insurance and the uninsured by calling (833) 808-1234. ...
Posted by Michael Wonder on 07 Apr 2020
Trump’s aggressive advocacy of malaria drug for treating coronavirus divides medical community
6 April 2020 - While Dr. Anthony Fauci has urged caution in using hydroxychloroquine, some doctors are prescribing it to patients ...
Posted by Michael Wonder on 07 Apr 2020
Esperion announces European Commission approval of the Nilemdo (bempedoic acid) tablet for the treatment of hypercholesterolaemia and mixed dyslipidaemia
6 April 2020 - First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients. ...
Posted by Michael Wonder on 07 Apr 2020
Novartis responds to social media criticism of Trump Administration promoting hydroxychloroquine
6 April 2020 - The pharmaceutical company Novartis responded to criticism leveled against it on social media on Monday about ...
Posted by Michael Wonder on 07 Apr 2020
Global plasma leaders collaborate to accelerate development of potential COVID-19 hyperimmune therapy
6 April 2020 - Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the ...
Posted by Michael Wonder on 07 Apr 2020
European Commission approves Takeda’s Alunbrig (brigatinib) as a first-line treatment for ALK+ NSCLC
6 April 2020 - Approval based on positive results from the Phase 3 ALTA-1L trial showing Alunbrig demonstrated superior overall and ...
Posted by Michael Wonder on 06 Apr 2020
States try reducing malaria drug hoarding amid unproven coronavirus benefit
5 April 2020 - Limits on filling prescriptions for hydroxychloroquine are aimed at preserving supplies for lupus, arthritis patients. ...
Posted by Michael Wonder on 06 Apr 2020
Read about a new COVID-19 treatment study? It probably won't work.
6 April 2020 - Most new drugs that show promise as potential COVID-19 cures will not end up working, scientists ...
Posted by Michael Wonder on 06 Apr 2020
COVID-19 update: daily roundup 6 April 2020
6 April 2020 - The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort ...
Posted by Michael Wonder on 06 Apr 2020
An update on COVID-19 from Gilead Chairman & CEO
4 April 2020 - Over the course of the past week, Gilead has been working in consultation with regulatory authorities ...
Posted by Michael Wonder on 06 Apr 2020
EU authorities agree new measures to support availability of medicines used in the COVID-19 pandemic
6 April 2020 - The continued availability of medicines, in particular those used for patients with COVID-19, is of critical ...